Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK)
Shanghai, CN
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solutions addressing various cardiovascular ailments. This includes specialized treatments for congenital heart defects, such as occluders for atrial septal, ventricular septal, and patent ductus arteriosus, along with necessary delivery systems and snare products. Additionally, it develops technologies for preventing cardioembolic stroke, offering occluders for the left atrial appendage and patent foramen ovale. Its portfolio also features a comprehensive selection of products for managing valvular diseases, including devices for aortic, mitral, tricuspid, and pulmonary valves, complemented by essential procedural accessories. Further offerings encompass vascular plugs and interatrial shunt devices. These medical technologies are primarily distributed to hospitals and through a network of distributors. Founded in 1994, the firm is headquartered in Shanghai, People's Republic of China, and operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | -21.55% | -16.65% | -39.71% | -46.04% | -40.24% | -58.03% | -64.60% | -67.03% | -67.03% | -67.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Specialty Business Services: +7.6%+11.9% ★ Q4'25: +23.9% (vs Q4'23)
-
EPS growth Specialty Business Services: +24.4%-2.8% Q4'25: -22.7% (vs Q4'23)
-
FCF margin FCF growth · Specialty Business Services: +27.6%+41.7% Q4'25: +11.5% (vs Q4'23)
-
EBIT margin Specialty Business Services: +9.0%+48.6% ★ Q4'25: +29.5% (vs Q4'23)
-
ROIC Specialty Business Services: +7.8%+25.2% ★ Q4'25: +23.3% (vs Q4'23)
-
Share dilution Specialty Business Services: +0.4%+0.0% Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Specialty Business Services: -0.21×0.01× ★ Q4'25: 0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
471.64M
est: 527.31M (-10.6%)
|
527.94M
est: 603.83M (-12.6%)
|
778.89M
763.77M – 794.00M
+29.0% YoY
|
983.89M
975.43M – 992.34M
+26.3% YoY
|
| EBITDA |
288.10M
est: 233.51M (+23.4%)
|
292.60M
est: 267.39M (+9.4%)
|
344.91M
338.22M – 351.60M
+29.0% YoY
|
435.69M
431.95M – 439.43M
+26.3% YoY
|
| EBIT |
286.26M
est: 209.89M (+36.4%)
|
256.81M
est: 240.34M (+6.8%)
|
310.02M
304.00M – 316.04M
+29.0% YoY
|
391.62M
388.25M – 394.98M
+26.3% YoY
|
| Net Income |
245.56M
est: 266.90M (-8.0%)
|
239.73M
est: 297.30M (-19.4%)
|
369.51M
328.14M – 410.89M
+24.3% YoY
|
433.78M
428.93M – 438.62M
+17.4% YoY
|
| SGA |
48.88M
est: 123.01M (-60.3%)
|
55.48M
est: 140.86M (-60.6%)
|
181.69M
178.16M – 185.22M
+29.0% YoY
|
229.51M
227.54M – 231.48M
+26.3% YoY
|
| EPS |
0.71
est: 0.77 (-7.8%)
|
0.69
est: 0.86 (-19.5%)
|
1.07
0.95 – 1.18
+24.3% YoY
|
1.25
1.24 – 1.26
+17.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.02% | 8.0K | 0.54% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.01% | 244.1K | 0.58% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 58.3K | 0.65% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 3.9K | 0.42% |
| 5 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 1.3K | 0.35% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 26.9K | 0.39% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 22.8K | 0.28% |
| 8 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 13.0K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Juan Chen | Executive Chairman & GM | 2M | female |
| Jinpeng Hu | Head of Research and Development of Occluder Division | — | male |
| Kejin Qiu | Head of Research & Development of Valve Division | — | male |
| Lai Shan Yeung | Joint Company Secretary | — | female |
| Xiani Zhang | Deputy General Manager | — | female |
| Xue Qin | Deputy GM, Chief Financial Officer & Joint Company Secretary | — | male |
| Yufeng He | Deputy GM & Chief Operating Officer | — | male |
| Jiadan Luo | Deputy General Manager | — | female |
| Zhangya Liao | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2291.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
